Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) have earned an average rating of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $11.00.
Several equities analysts have recently weighed in on DRNA shares. HC Wainwright restated a “buy” rating and issued a $10.00 price objective (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $6.25 price objective for the company in a report on Monday, October 23rd. BidaskClub cut Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Chardan Capital reiterated a “neutral” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, January 16th. Finally, Evercore ISI started coverage on Dicerna Pharmaceuticals in a report on Tuesday, January 16th. They set an “outperform” rating and a $14.00 price target for the company.
In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Monday, December 18th. The stock was acquired at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 29.41% of the company’s stock.
Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up $0.67 during midday trading on Tuesday, hitting $9.61. The stock had a trading volume of 306,256 shares, compared to its average volume of 425,654. The company has a market cap of $469.42, a PE ratio of -2.80 and a beta of 2.75. Dicerna Pharmaceuticals has a 12 month low of $2.43 and a 12 month high of $11.19.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22). The company had revenue of $0.47 million during the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. Dicerna Pharmaceuticals’s quarterly revenue was up 192.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.68) EPS. research analysts anticipate that Dicerna Pharmaceuticals will post -2.93 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://stocknewstimes.com/2018/02/13/dicerna-pharmaceuticals-inc-drna-given-average-rating-of-hold-by-brokerages.html.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.